Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Fehse, Boris  [Clear All Filters]
Journal Article
Schambach A, Morgan M, Fehse B. Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy. Mol Ther. 2021.
Nikitenko NA, Speiseder T, Groitl P, Spirin PV, Prokofjeva MM, Lebedev TD, Rubtsov PM, Lam E, Riecken K, Fehse B, et al. Targeting species D adenoviruses replication to counteract the epidemic keratoconjunctivitis. Biochimie. 2015.
Luther M, Henes FOliver, Zabelina T, Massoud R, Janson D, Wolschke C, Klyuchnikov E, Gagelmann N, Fehse B, Adam G, et al. Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2023.
Zecher BF, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick ME, Yuki Y, Martin MP, Glow D, Schröder-Schwarz J, et al. is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells. Gut. 2023.
Zhan H, Gilmour K, Chan L, Farzaneh F, McNicol AMarie, Xu J-H, Adams S, Fehse B, Veys P, Thrasher A, et al. Production and First-in-Man Use of T Cells Engineered to Express a HSVTK-CD34 Sort-Suicide Gene. PLoS One. 2013;8(10):e77106.
Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuk F. Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins. Oncotarget. 2016.
Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, Fehse B, Bacher U, Kröger N. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia. 2024.
Hossain JA, Ystaas LRømo, Mrdalj J, Välk K, Riecken K, Fehse B, Bjerkvig R, Grønli J, Miletic H. Lentiviral HSV-Tk.007 mediated suicide gene therapy is not toxic for normal brain cells. J Gene Med. 2016.
Gomez-Nicola D, Riecken K, Fehse B, V Perry H. In-vivo RGB marking and multicolour single-cell tracking in the adult brain. Sci Rep. 2014;4:7520.
Jung G, Sun J, Petrowitz B, Riecken K, Kruszewski K, Jankowiak W, Kunst F, Skevas C, Richard G, Fehse B, et al. Genetically Modified Neural Stem Cells for a Local and Sustained Delivery of Neuroprotective Factors to the Dystrophic Mouse Retina. Stem Cells Transl Med. 2013.
Triviai I, Ziegler M, Bergholz U, Oler AJ, Stübig T, Prassolov V, Fehse B, Kozak CA, Kröger N, Stocking C. Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis. Proc Natl Acad Sci U S A. 2014.
Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, Ayuk F, Fehse B, Kröger N. Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation. Hemasphere. 2023;7(7):e921.
Stahl T, Böhme M, Kröger N, Fehse B. Digital PCR to assess haematopoietic chimaerism after allogeneic stem cell transplantation. Exp Hematol. 2015.
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger JS, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, et al. Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget. 2015;6(8):6341-6358.
Schwarze LIsabell, Głów D, Sonntag T, Uhde A, Fehse B. Correction: Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application. Gene Ther. 2022.
Grochowska KM, Sperveslage M, Raman R, Failla AV, Głów D, Schulze C, Laprell L, Fehse B, Kreutz MR. Chaperone-mediated autophagy in neuronal dendrites utilizes activity-dependent lysosomal exocytosis for protein disposal. Cell Rep. 2023;42(8):112998.
Roh V, Abramowski P, Hiou-Feige A, Cornils K, Rivals J-P, Zougman A, Aranyossy T, Thielecke L, Truan Z, Mermod M, et al. Cellular Barcoding Identifies Clonal Substitution as a Hallmark of Local Recurrence in a Surgical Model of Head and Neck Squamous Cell Carcinoma. Cell Rep. 2018;25(8):2208-2222.e7.
Fischbach F, Richter J, Pfeffer LKristina, Fehse B, Berger SCarolina, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024.
Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, Stocking C, Kröger N. CD133 marks a stem cell population that drives human Primary Myelofibrosis. Haematologica. 2015.
Ayuk F, Fehse B. CARs come to AID. Mol Ther. 2024.
Fehse B, Tomas NM. The authors reply. Kidney Int. 2024;105(6):1320-1321.
Seifert L, Riecken K, Zahner G, Hambach J, Hagenstein J, Dubberke G, Huber TB, Koch-Nolte F, Fehse B, Tomas NM. An antigen-specific chimeric autoantibody receptor NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells. Kidney Int. 2024.
Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder TMC, Fehse B, Kröger N. 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm. 2014;2014:418292.